ATE284538T1 - Komplex, bestehend aus einem chaperon und beta- amyloidprotein sowie verfahren, die diesen komplex benutzen - Google Patents
Komplex, bestehend aus einem chaperon und beta- amyloidprotein sowie verfahren, die diesen komplex benutzenInfo
- Publication number
- ATE284538T1 ATE284538T1 AT99961552T AT99961552T ATE284538T1 AT E284538 T1 ATE284538 T1 AT E284538T1 AT 99961552 T AT99961552 T AT 99961552T AT 99961552 T AT99961552 T AT 99961552T AT E284538 T1 ATE284538 T1 AT E284538T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- complex
- level
- alzheimer
- biological sample
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10639898P | 1998-10-30 | 1998-10-30 | |
US12356499P | 1999-03-10 | 1999-03-10 | |
PCT/US1999/025593 WO2000026251A2 (en) | 1998-10-30 | 1999-10-29 | A COMPLEX OF A CHAPERONE WITH ss-AMYLOID AND METHODS EMPLOYING THIS COMPLEX |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE284538T1 true ATE284538T1 (de) | 2004-12-15 |
Family
ID=26803625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99961552T ATE284538T1 (de) | 1998-10-30 | 1999-10-29 | Komplex, bestehend aus einem chaperon und beta- amyloidprotein sowie verfahren, die diesen komplex benutzen |
Country Status (12)
Country | Link |
---|---|
US (3) | US6972318B1 (de) |
EP (1) | EP1125135B1 (de) |
JP (1) | JP4571310B2 (de) |
AT (1) | ATE284538T1 (de) |
AU (1) | AU764713B2 (de) |
CA (1) | CA2348545C (de) |
DE (1) | DE69922535T2 (de) |
IL (2) | IL142852A0 (de) |
MX (1) | MXPA01004317A (de) |
NO (1) | NO331974B1 (de) |
NZ (1) | NZ511589A (de) |
WO (1) | WO2000026251A2 (de) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1289512B1 (de) * | 2000-05-24 | 2005-03-09 | Jordan L. Holtzman | Mittel und verfahren zur erhöhung des chaperonin-spiegels im gehirn |
US7094884B2 (en) | 2001-06-22 | 2006-08-22 | Roche Diagnostics Corporation | Soluble complexes of amylod β peptide and peptidyl prolyl isomerase chaperone and methods of making and using them |
US6962982B2 (en) | 2001-06-22 | 2005-11-08 | Roche Diagnostics Corporation | Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them |
US7094757B2 (en) | 2001-06-22 | 2006-08-22 | Roche Diagnostics Corporation | Complexes comprising a prion protein and a peptidyl prolyl isomerase chaperone, and method for producing and using them |
ATE374784T1 (de) * | 2002-12-20 | 2007-10-15 | Hoffmann La Roche | Lösliche komplexe von zielproteinen und peptidyl- prolyl-isomerase-chaperonen sowie deren herstellung und verwendung |
US9335331B2 (en) * | 2005-04-11 | 2016-05-10 | Cornell Research Foundation, Inc. | Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject |
JP4981305B2 (ja) * | 2005-11-11 | 2012-07-18 | 公益財団法人大阪バイオサイエンス研究所 | アルツハイマー病の発症リスク又はアルツハイマー病発症予後の予測方法 |
US8592844B2 (en) * | 2010-01-29 | 2013-11-26 | Nitto Denko Corporation | Light-emitting diode device |
US9522170B2 (en) | 2011-04-05 | 2016-12-20 | Alphabeta Ab | Methods of screening compounds for the fibril formation of Aβ peptides based on a decreased trimer/monomer ratio of a chaperone protein |
US20140302532A1 (en) | 2011-04-12 | 2014-10-09 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury |
WO2014012108A1 (en) * | 2012-07-13 | 2014-01-16 | Holtzman Jordan L | Cellular and animal models for screening therapeutic agents for the treatment of alzheimer's disease |
WO2018067854A1 (en) * | 2016-10-06 | 2018-04-12 | Ramp Research, Llc | Methods, compositions, and kits involving alteration of the chaperone protein axis in a subject |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223482A (en) * | 1986-11-17 | 1993-06-29 | Scios Nova Inc. | Recombinant Alzheimer's protease inhibitory amyloid protein and method of use |
US5780587A (en) | 1990-08-24 | 1998-07-14 | President And Fellows Of Harvard College | Compounds and methods for inhibiting β-protein filament formation and neurotoxicity |
US5750349A (en) * | 1993-01-25 | 1998-05-12 | Takeda Chemical Industries Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
US5707821A (en) * | 1995-06-07 | 1998-01-13 | Athena Neurosciences, Inc. | Identification of phospholipase A2 inhibitors in Aβ peptide-mediated neurodegenerative disease |
JPH09178743A (ja) * | 1995-12-27 | 1997-07-11 | Oriental Yeast Co Ltd | 可溶性appの定量法 |
JP2001525390A (ja) | 1997-12-10 | 2001-12-11 | エヌピーエス ファーマシューティカルズ インコーポレーテッド | 抗痙攣薬および中枢神経系活性ビス(フルオロフェニル)アルキルアミド類 |
-
1999
- 1999-10-29 MX MXPA01004317A patent/MXPA01004317A/es active IP Right Grant
- 1999-10-29 DE DE69922535T patent/DE69922535T2/de not_active Expired - Lifetime
- 1999-10-29 EP EP99961552A patent/EP1125135B1/de not_active Expired - Lifetime
- 1999-10-29 AT AT99961552T patent/ATE284538T1/de not_active IP Right Cessation
- 1999-10-29 CA CA2348545A patent/CA2348545C/en not_active Expired - Fee Related
- 1999-10-29 WO PCT/US1999/025593 patent/WO2000026251A2/en active IP Right Grant
- 1999-10-29 IL IL14285299A patent/IL142852A0/xx unknown
- 1999-10-29 JP JP2000579637A patent/JP4571310B2/ja not_active Expired - Fee Related
- 1999-10-29 AU AU18105/00A patent/AU764713B2/en not_active Ceased
- 1999-10-29 US US09/830,749 patent/US6972318B1/en not_active Expired - Lifetime
- 1999-10-29 NZ NZ511589A patent/NZ511589A/en not_active IP Right Cessation
-
2001
- 2001-04-27 NO NO20012114A patent/NO331974B1/no not_active IP Right Cessation
- 2001-04-29 IL IL142852A patent/IL142852A/en not_active IP Right Cessation
-
2005
- 2005-09-19 US US11/231,065 patent/US7927824B2/en not_active Expired - Fee Related
-
2011
- 2011-04-19 US US13/089,940 patent/US8211658B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NO331974B1 (no) | 2012-05-14 |
IL142852A0 (en) | 2002-03-10 |
AU764713B2 (en) | 2003-08-28 |
JP2002528555A (ja) | 2002-09-03 |
WO2000026251A3 (en) | 2000-08-10 |
DE69922535D1 (de) | 2005-01-13 |
US20110256569A1 (en) | 2011-10-20 |
EP1125135B1 (de) | 2004-12-08 |
US6972318B1 (en) | 2005-12-06 |
US7927824B2 (en) | 2011-04-19 |
NO20012114D0 (no) | 2001-04-27 |
IL142852A (en) | 2010-05-31 |
MXPA01004317A (es) | 2003-06-06 |
NZ511589A (en) | 2005-02-25 |
CA2348545A1 (en) | 2000-05-11 |
CA2348545C (en) | 2012-08-21 |
AU1810500A (en) | 2000-05-22 |
US8211658B2 (en) | 2012-07-03 |
WO2000026251A2 (en) | 2000-05-11 |
EP1125135A2 (de) | 2001-08-22 |
US20060024759A1 (en) | 2006-02-02 |
WO2000026251A9 (en) | 2001-01-04 |
JP4571310B2 (ja) | 2010-10-27 |
DE69922535T2 (de) | 2005-05-12 |
NO20012114L (no) | 2001-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE284538T1 (de) | Komplex, bestehend aus einem chaperon und beta- amyloidprotein sowie verfahren, die diesen komplex benutzen | |
Possin et al. | Cross-species translation of the Morris maze for Alzheimer’s disease | |
EP2293075A3 (de) | Verfahren zur Diagnose neurodegenerativer Erkrankungen | |
ATE376187T1 (de) | Nachweis von erkrankungen der nieren und behandlung | |
ATE479490T1 (de) | Verfahren zum trennen von seltenen zellen von fluidproben | |
El-Mezayen et al. | Diagnostic performance of collagen IV and laminin for the prediction of fibrosis and cirrhosis in chronic hepatitis C patients: a multicenter study | |
ATE197964T1 (de) | Bestimmung von mutationen im zusammenhang mit dem digeorge-syndrom | |
Martinelli et al. | Heightened thrombin generation in individuals with resistance to activated protein C | |
Gurgey et al. | Factor V Leiden mutation and PAI-1 gene 4G/5G genotype in thrombotic patients with Behcet's disease | |
DE60331857D1 (de) | Markerproteine zur diagnose einer lebererkrankung und verfahren zur diagnose einer lebererkrankung damit | |
DE69204157D1 (de) | Verfahren zur bestimmung von anti-rns-antikörpern. | |
ATE139803T1 (de) | Allelische verbindung des humanen dopamin- (d2)rezeptor-gens in kompulsionsstörungen wie alkoholismus | |
JP2006300689A (ja) | 肝疾患病態判定用マーカー及び該マーカーを用いる肝疾患病態判定方法 | |
DE60129015D1 (de) | Verfahren zur erkennung von entzündungen und entzündungsbedingungen | |
Morange et al. | Ala147Thr and C+ 1542G polymorphisms in the TAFI gene are not asssociated with a higher risk of venous thrombosis in FV Leiden carriers | |
Peake et al. | Type 1 von Willebrand disease | |
FI990380A0 (fi) | Diagnostinen ja seulontamenetelmä | |
Durany et al. | Increased frequency of the α‐1‐antichymotrypsin T allele in cerebral amyloid angiopathy | |
Bhakdi et al. | A simple method for quantitative measurement of C3d in human plasma | |
Hota et al. | Role of eosinophil count and neutrophil: lymphocyte count ratio as prognostic markers in patients with sepsis | |
ATE515576T1 (de) | Protein c polymorphismen | |
Gupta et al. | Quantification of plasma fibrinogen degradation products in areca nut chewers with and without oral submucous fibrosis | |
Hani et al. | The value of family screening for patients with cystine stone disease in northern Jordan | |
Saboor et al. | Correlation of Antithrombin Functional Status and Levels with Liver Fibrosis in Patients with Hepatitis C. | |
Dunn et al. | Evaluation of role of factor V Leiden mutation in fatal pulmonary thromboembolism |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |